Clinical Trial Detail

NCT ID NCT01231594
Title A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

Advanced Solid Tumor

Therapies

Dabrafenib

Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST